同类型展品
展品详情
产品：诺和忻®
产品介绍：诺和忻®（司美格鲁肽片）是一种GLP-1受体激动剂，在饮食控制和运动基础上，适用于控制不佳的成人2型糖尿病患者，以改善其血糖控制。诺和忻®每天给药一次，已获批三种剂量：3 mg, 7 mg和14 mg。相较于Januvia®和Jardiance®，诺和忻®可实现优效的血糖降幅，同时兼具体重下降，并能降低心血管代谢风险因素。诺和忻®目前已在45个国家商业上市。全球共有210多万2型糖尿病患者正在接受诺和忻®治疗。
About Rybelsus®
Rybelsus® (oral semaglutide) is a GLP-1 receptor agonist indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise. Rybelsus® is administered once daily and is approved for use in three therapeutic dosages, 3 mg, 7 mg and 14 mg. Rybelsus® offers superior blood glucose lowering vs Januvia® and Jardiance®, together with consistent weight reduction and reduction in cardiometabolic risk factors. Rybelsus® is currently commercially marketed in 45 countries. More than 2.1 million people with type 2 diabetes are currently being treated with Rybelsus® worldwide.